FRAZER, Pa., and CAMBRIDGE, Mass., June 13 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH - News) and Alkermes, Inc. (Nasdaq: ALKS - News) today announced that VIVITROL(TM) (naltrexone for extended-release injectable suspension), the first and only once-monthly injectable medication for alcohol dependence, is now commercially available in the United States. VIVITROL is indicated for patients who are able to abstain from drinking in an outpatient setting and are not actively drinking when initiating treatment. VIVITROL should be used as part of a comprehensive treatment management program, which includes psychosocial support, such as counseling or group therapy.
